Your browser doesn't support javascript.
loading
Seek COVER: Development and validation of a personalized risk calculator for COVID-19 outcomes in an international network
Ross D. Williams; Aniek F. Markus; Cynthia Yang; Talita Duarte Salles; Scott L Duvall; Thomas Falconer; Jitendra Jonnagaddala; Chungsoo Kim; Yeunsook Rho; Andrew Williams; Amanda Alberga; Min Ho An; María Aragón; Carlos Areia; Edward Burn; Young Choi; Iannis Drakos; Maria Fernandes Abrahão; Sergio Fernández-Bertolín; George Hripcsak; Benjamin Kaas-Hansen; Prasanna Kandukuri; Jan A. Kors; Kristin Kostka; Siaw-Teng Liaw; Kristine E Lynch; Michael E Matheny; Gerardo Machnicki; Daniel Morales; Fredrik Nyberg; Rae Woong Park; Albert Prats-Uribe; Nicole Pratt; Gowtham Rao; Christian G. Reich; Marcela Rivera; Tom Seinen; Azza Shoaibi; Matthew E. Spotnitz; Ewout W. Steyerberg; Marc A Suchard; Seng Chan You; Lin Zhang; Lili Zhou; Patrick B. Ryan; Daniel Prieto-Alhambra; Jenna M. Reps; Peter R. Rijnbeek.
Afiliación
  • Ross D. Williams; Erasmus University Medical Center
  • Aniek F. Markus; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
  • Cynthia Yang; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
  • Talita Duarte Salles; Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol)
  • Scott L Duvall; Department of Veterans Affairs, USA; University of Utah, USA
  • Thomas Falconer; Department of Biomedical Informatics, Columbia University, New York, NY
  • Jitendra Jonnagaddala; School of Public Health and Community Medicine, UNSW Sydney
  • Chungsoo Kim; Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea
  • Yeunsook Rho; Department of Bigdata, Health Insurance Review & Assessment Service, Republic of Korea
  • Andrew Williams; Tufts Institute for Clinical Research and Health Policy Studies, Boston, MA, 02111, USA
  • Amanda Alberga; Independent Epidemiologist, OHDSI
  • Min Ho An; Wando county health center and hospital
  • María Aragón; Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol)
  • Carlos Areia; Nuffield Department of Clinical Neurosciences, University of Oxford
  • Edward Burn; University of Oxford
  • Young Choi; Department of Infectious Diseases, Ajou University School of Medicine, Suwon, Republic of Korea
  • Iannis Drakos; Center for Surgical Science, Koege, Denmark
  • Maria Fernandes Abrahão; Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil
  • Sergio Fernández-Bertolín; Fundacio Institut Universitari per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol)
  • George Hripcsak; Department of Biomedical Informatics, Columbia University, New York, NY
  • Benjamin Kaas-Hansen; Clinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark NNF Centre for Protein Research, University of Copenhagen, Denmark
  • Prasanna Kandukuri; Abbvie, Chicago, United States
  • Jan A. Kors; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
  • Kristin Kostka; Real World Solutions, IQVIA, Cambridge, MA, United States
  • Siaw-Teng Liaw; School of Public Health and Community Medicine, UNSW Sydney
  • Kristine E Lynch; Department of Veterans Affairs, USA; University of Utah, USA
  • Michael E Matheny; Department of Veterans Affairs, USA; Vanderbilt University, USA
  • Gerardo Machnicki; Janssen Latin America, Buenos Aires, Argentina
  • Daniel Morales; Division of Population Health and Genomics, University of Dundee, UK
  • Fredrik Nyberg; School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg Gothenburg, Sweden
  • Rae Woong Park; Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea
  • Albert Prats-Uribe; University of Oxford
  • Nicole Pratt; Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Adelaide, Australia
  • Gowtham Rao; Janssen Research & Development, Titusville, NJ, USA
  • Christian G. Reich; Real World Solutions, IQVIA, Cambridge, MA, United States
  • Marcela Rivera; Bayer Pharmaceuticals, Bayer Hispania, S.L., Barcelona, Spain
  • Tom Seinen; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
  • Azza Shoaibi; Janssen Research & Development, Titusville, NJ, USA
  • Matthew E. Spotnitz; mes2165@cumc.columbia.edu
  • Ewout W. Steyerberg; Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands, Department of Biomedical Data Sciences, Leiden University Medical Ce
  • Marc A Suchard; Department of Biostatistics, UCLA Fielding School of Public Health, University of California, Los Angeles, CA, USA
  • Seng Chan You; Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea
  • Lin Zhang; School of Population and Global Health, The University of Melbourne & WHO Collaborating Centre on Im
  • Lili Zhou; Abbvie, Chicago, United States
  • Patrick B. Ryan; Janssen Research & Development, Titusville, NJ, USA
  • Daniel Prieto-Alhambra; University of Oxford
  • Jenna M. Reps; Janssen Research & Development, Titusville, NJ, USA
  • Peter R. Rijnbeek; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-20112649
ABSTRACT
ObjectiveTo develop and externally validate COVID-19 Estimated Risk (COVER) scores that quantify a patients risk of hospital admission (COVER-H), requiring intensive services (COVER-I), or fatality (COVER-F) in the 30-days following COVID-19 diagnosis. MethodsWe analyzed a federated network of electronic medical records and administrative claims data from 14 data sources and 6 countries. We developed and validated 3 scores using 6,869,127 patients with a general practice, emergency room, or outpatient visit with diagnosed influenza or flu-like symptoms any time prior to 2020. The scores were validated on patients with confirmed or suspected COVID-19 diagnosis across five databases from South Korea, Spain and the United States. Outcomes included i) hospitalization with pneumonia, ii) hospitalization with pneumonia requiring intensive services or death iii) death in the 30 days after index date. ResultsOverall, 44,507 COVID-19 patients were included for model validation. We identified 7 predictors (history of cancer, chronic obstructive pulmonary disease, diabetes, heart disease, hypertension, hyperlipidemia, kidney disease) which combined with age and sex discriminated which patients would experience any of our three outcomes. The models achieved high performance in influenza. When transported to COVID-19 cohorts, the AUC ranges were, COVER-H 0.69-0.81, COVER-I 0.73-0.91, and COVER-F 0.72-0.90. Calibration was overall acceptable. ConclusionsA 9-predictor model performs well for COVID-19 patients for predicting hospitalization, intensive services and fatality. The models could aid in providing reassurance for low risk patients and shield high risk patients from COVID-19 during de-confinement to reduce the virus impact on morbidity and mortality.
Licencia
cc_by_nc_nd
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Cohort_studies / Observational_studies / Prognostic_studies Idioma: En Año: 2020 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Cohort_studies / Observational_studies / Prognostic_studies Idioma: En Año: 2020 Tipo del documento: Preprint